Topic

Articles

Pharm Exec speaks with Adams about how his company developed a new medicine designed to meet migraine patients’ needs.

Q&A With Adrian Adams, chairman and chief executive officer of Impel Pharmaceuticals

Managing Vice President at the Philadelphia Office of Pariveda

Industry has shown it can overcome challenges en route to creating new therapies.

What the COVID-19 Vaccine Process Showed Us, and How It Can Impact the Future of Drug Development

Vice President of Analytics and Insights Management, Array

New mediums of technology must be utilized correctly to reap full benefits.

If Content Is King, Context Is the Power Behind the Throne

From exposing disparities in care to guiding better patient outcomes to helping reign in the costs of care, the use of real-world data (RWD) in oncology can have far-reaching effects. Here’s how one RWD company exec is using her experience to help drive that change.

Q&A With Miruna Sasu, president and CEO, COTA, Inc.

Global Head of Thought Leadership, Decision Resources Group, Clarivate

With added push from the COVID-19 pandemic, investment in promising RNA- and cell and gene therapy-based treatments and technology via industry dealmaking is growing considerably.

Next-Gen Partnerships: The Ascent of Advanced Therapies  

Foster talks to Pharm Exec about why liver disease is on the rise, and Hepion’s new therapy, rencofilstat, in development to treat it.

Q&A With Robert Foster, CEO of Hepion Pharmaceuticals

Genomic data is transforming precision medicine—but progress depends on it being easily available where it’s needed. Pharmaceutical Executive speaks to Ignacio Medina, founder of Cambridge University spinout Zetta Genomics, to see how next-generation open-source data technologies accelerate discovery in the lab and patient benefit in the clinic.

Q&A With Ignacio Medina, founder, Zetta Genomics

It takes flexibility and adaptability to switch a company’s focus. Here, Alkermes’ Chief Operating Officer Blair Jackson discusses how his team pivoted from developing CNS to oncology therapies and the skills it required.

Q&A With Blair Jackson, Chief Operating Officer, Alkermes

Rush shares his thoughts on how advanced analytics are making their mark on the pharma industry.

Q&A with Daniel Rush, PhD, senior vice president of strategy and transformation at Waters Corporation

Executive Director, IQVIA Institute for Human Data Science

Despite disruption from the COVID-19 pandemic still in full swing, life sciences innovation activity remained undeterred, a recent report from the IQVIA Institute for Human Data Science finds—outlining the key factors driving record-breaking growth.

R&D/Clinical Trials